Google Académico | Citações: 16429 | índice h: 32 | índice i10: 482
Resumen de los niveles de tacrolimusen pacientes contrasplante renal em um hospital de Ceará
PDF (portugués (Brasil))

Palabras clave

Inmunosupresores
Interacciones Farmacológicas
Monitoreo de Drogas
Trasplante de Riñón

Cómo citar

Resumen de los niveles de tacrolimusen pacientes contrasplante renal em um hospital de Ceará. (2025). Revista Eletrônica Acervo Saúde, 25(5), e20290. https://doi.org/10.25248/reas.e20290.2025

Copyright © | Todos los derechos reservados.

La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.

Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.

Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.

Resumen

Objetivo: Correlacionar la medicación y los factores asociados con los cambios en los niveles de tacrolimus en pacientes postrasplante en un Hospital Universitario de Ceará. Métodos: Estudio observacional retrospectivo con datos de historias clínicas (n=181) (marzo/2019-mayo/2022). Se evaluaron variables sociodemográficas, comorbilidades, niveles de tacrolimus en sangre (en la fecha, 30 días y 1 año después del alta) y la farmacoterapia utilizada al alta. Resultados: Predominaban los pacientes varones de entre 31 y 59 años que no sabían leer ni escribir a nivel de primer grado. Además, predominaban los pacientes hipertensos, diabéticos y dislipidémicos. La hospitalización media fue de 21,52 ± 16,11 días, y el 64,1% de los pacientes utilizaron entre 5 y 10 fármacos. Se detectaron interacciones de los inmunosupresores utilizados con anlodipino, isoniazida, omeprazol y prednisona. Treinta días y un año después del alta, los cambios en los niveles de tacrolimus fueron reducidos (p = 0,0029). Hubo una correlación entre la edad y los niveles de tacrolimus al alta (Rho = 0,169; p = 0,023) y un modelo de regresión lineal en el que la diabetes mellitus predice un aumento de 1,195 ng/mL (IC 95% = 0,436-1,955) en la concentración de tacrolimus al alta [X2(1; n=181) = 9,655; R2 = 0,051; p = 0,002]. Conclusión: Se puede concluir que la edad y la diabetes mellitus son factores que pueden interferir en la concentración de tacrolimus y que existe una mayor necesidad de monitorizar a los pacientes postrasplante.

PDF (portugués (Brasil))

Referencias

ABDELHALIM MS, et al. The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. Kidney Research and Clinical Practice, 2020; 39(4): 479–486.

ABTO. Registro Brasileiro de Transplantes. 2024. Disponível em: https://site.abto.org.br/wp-content/uploads/2024/05/RBT-2024-jan-mar_POPULACAO.pdf. Acessado em: 18 de novembro de 2024.

AZEVEDO G, et al. Fisiopatologia e diagnóstico da nefropatia diabética: uma revisão integrativa / Physiopathologyanddiagnosisofdiabeticnephropathy: anintegrative review. BrazilianJournalof Health Review, 2022; 5(1): 3615–3637.

BRASIL. Protocolo Clínico e Diretrizes Terapêuticas-Imunossupressão em Transplante Renal.Disponível em: https://www.gov.br/saude/pt-br/assuntos/pcdt/arquivos/2021/imunossupressao-em-transplante-renal-pcdt.pdf. Acessado em: 18 de novembro de 2024.

BRUNET M, et al. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic drug monitoring, 2019; 41(3): 261–307.

BRUNET M, PASTOR-ANGLADA M. Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics. Pharmaceutics, 2022; 14(9).

CHEN HX, et al. Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome. World journal of pediatrics: WJP, 2020; 16(2): 159–167.

CIFTCI HS, et al. Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism. Transplantation Proceedings, 2017;49(3): 490–496.

FRAGA JM, et al. Fatores que influenciam o tempo de internação no transplante renal. Saúde Coletiva (Barueri), 2021; 11(68): 7617–7628.

GAL A, BURCHELL RK. Diabetes Mellitus and the Kidneys. The Veterinary clinics of North America. Small animal practice, 2023; 53(3): 565–580.

GALATO D, et al.Avaliação do Índice de Complexidade da Farmacoterapia em Pacientes de um Ambulatório de Transplante Renal. BrazilianJournalofTransplantation, 2022; 25(2).

GARCIA CD, et al. Manual de Doação e Transplantes, 2017. Disponível em: https://site.abto.org.br/wp-content/uploads/2020/08/Manual-dos-transplantesebook-versao-2022_compressed-1.pdf. Acessado em: 7 de fevereiro de 2025.

GODT. Global Observatory on Donation and Transplantation. Disponível em: https://www.transplant-observatory.org/. Acessadoem: 18 de novembro de 2024.

GOICOCHEA-RIOS EDS, et al. Factors Associated with the Development of Chronic Kidney Disease in Patients with Arterial Hypertension. Internationaljournalofnephrologyand renovascular disease, 2024; 17: 113–123.

GOUVÊA ECDP, et al.Self-report of medical diagnosis of chronic kidney disease: prevalence and characteristics in the Brazilian adult population, National Health Survey 2013 and 2019. Epidemiologia e Servicos de Saude, 2022; 31(nspe1): e2021385.

IBGE. Pesquisa nacional de saúde: Percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal: Brasil e grandes regiões. Disponível em: https://biblioteca.ibge.gov.br/visualizacao/livros/liv101764.pdf. Acessado em: 18 de novembro de 2024.

KUMONDAI M, et al. Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors. Tohoku Journal of Experimental Medicine, 2023; 260(1): 29–34.

LI Y, et al. Investigation of pharmacologic interactions between omeprazole and tacrolimus in a membranous nephropathy patient with CYP3A5 nonexpresser: a case report. Pharmacogenetics and genomics, 2022; 32(7): 268–271.

LIN YN, et al. Oleanolic Acid-Mediated Inhibition of Pregnane X Receptor and Constitutive Androstane Receptor Attenuates Rifampin-Isoniazid Cytotoxicity. Journal of agricultural and food chemistry, 2017; 65(39): 8606–8616.

MAGRO PSD, et al. Kidney transplantation and perioperative complications: a prospective cohort study. Brazilian Journal of Anesthesiology, 2024; 74(6): 844556.

MEDEIROS LKA, et al. Fatores associados à adesão a terapia imunossupressora em indivíduos transplantados renais. Enferm. foco (Brasília), 2022; 13: 1–6.

MIEDZIASZCZYK M, IDASIAK-PIECHOCKA I. Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients – A review. Biomedicine and Pharmacotherapy, 2023; 166: 115149.

MOES AD, et al. Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. American journal of kidney diseases: the official journal of the National Kidney Foundation, 2017; 69(6): 796–804.

MOES DJAR, et al. Sirolimus and everolimus in kidney transplantation. Drug discovery today, 2015; 20(10): 1243–1249.

NASCIMENTO L, et al. Economic Impact of Pharmaceutical Recommendations Carried Out in a Liver Transplant Unit of a University Hospital. Brazilian Journal of Transplantation, 2024; 27(1): e1424.

OOSTING IJ, et al. Polypharmacy in Patients with CKD: A Systematic Review and Meta-Analysis. Kidney360, 2024; 5(6): 841-850.

PARLAKPINAR H, GUNATA M. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs. Immunopharmacology and immunotoxicology, 2021; 43(6): 651–665.

PRETTO CR, et al. Quality of life of chronic kidney patients on hemodialysis and related factors. Revista Latino-Americana de Enfermagem, 2020; 28: e3327.

ROCHA KT, FIGUEIREDO AE. Health literacy: Assessment of patients in renal replacement therapy. EnfermeriaNefrologica, 2019; 22(4): 388–397.

SANTOS LF, et al. A má administração medicamentosa de analgésicos e anti-inflamatórios em idosos. Rev. Terra & Cult.,2022; 38: 278-296.

SHI YX, et al. Efficacy of Adherence-Enhancing Interventions for Immunosuppressive Therapy in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials. Frontiers in Pharmacology, 2020; 11: 578887.

SOARES ACO, et al. Determinants of access to hemodialysis services in a metropolitan region of Brazil. BMC Public Health, 2022; 22: 1868.

SOUSA LCM, et al. Health-related patterns and chronic kidney disease in the Brazilian population: National Health Survey, 2019. Frontiers in Public Health, 2023; 11: 1090196.

SUNDERLAND A, et al. Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolicACid exposure in kidney and liver transplant recipienTs (IMPACT study): A randomized trial. Nephrology Dialysis Transplantation, 2020; 35(6): 1060–1070.

SZUMILAS K. et al. Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation. InternationalJournalof Molecular Sciences, 2023; 24(12): 10301.

TAMMISETTI VS, et al. Immunosuppressive Therapy in Solid Organ Transplantation: Primer for Radiologists and Potential Complications. Radiologic Clinics of North America, 2023; 61(5): 913–932.

TKACHUK O. Fisiopatologia da Hipertensão Arterial na Doença Renal Crónica. Dissertação (Mestrado Integrado em Medicina). Universidade de Coimbra, Portugal, 2019; 41 p.

YANG Y, et al. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. Frontiers in Pharmacology, 2021; 12: 692922.

ZWART TC, et al. Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. Drug discovery today, 2021; 26(11): 2527–2546.